SPDB-DM4 CAS:1626359-62-3 is an advanced drug-linker conjugate designed for the development of antibody-drug conjugates (ADCs) in cancer therapy. This innovative compound features the potent maytansine-based payload DM4, a tubulin inhibitor, coupled to a highly efficient N-succinimidyl-4-(2-pyridyldithio)butanoate (SPDB) linker. The unique combination of DM4 and the SPDB linker allows for the targeted delivery of the cytotoxic agent, resulting in potent anti-tumor activity.
SPDB-DM4 is a versatile research tool with potential applications in the design and optimization of ADCs for cancer therapy. Its superior conjugation efficiency and stability make it an ideal candidate for the development of next-generation targeted drug delivery systems. The powerful DM4 payload, a tubulin inhibitor, disrupts microtubule dynamics, leading to cell cycle arrest and subsequent apoptosis in targeted cancer cells. By leveraging the unique properties of SPDB-DM4, researchers can explore new avenues for targeted cancer therapeutics, contributing to the advancement of more effective and safer treatments for various malignancies.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.